SG
VIR icon

StoneX Group’s Vir Biotechnology VIR Stock Holding History

StoneX Group’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-11,762
Closed -$289K – 735
2023
Q2 		$289K Buy
11,762
+91
+0.8% +$2.29K 0.03% 414
2023
Q1 		$272K Sell
11,671
-314
-3% -$8.03K 0.03% 438
2022
Q4 		$303K Sell
11,985
-120
-1% -$2.94K 0.04% 382
2022
Q3 		$233K Sell
12,105
-765
-6% -$19.4K 0.03% 411
2022
Q2 		$328K Sell
12,870
-2,247
-15% -$52.5K 0.04% 390
2022
Q1 		$389K Sell
15,117
-1,884
-11% -$55.9K 0.03% 412
2021
Q4 		$712K Sell
17,001
-2,110
-11% -$82.7K 0.08% 229
2021
Q3 		$832K Sell
19,111
-1,020
-5% -$44.2K 0.12% 183
2021
Q2 		$952K Buy
20,131
+387
+2% +$17.6K 0.14% 158
2021
Q1 		$1.01M Buy
+19,744
New +$1.06M 0.18% 110

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

StoneX Group's VIR Position: Q3 2023 in Review

StoneX Group sold out of Vir Biotechnology (VIR) in Q3 2023, closing a stake of 11,762 shares — an estimated $289K sold.

StoneX Group first reported a position in VIR in Q1 2021 and held it in 10 quarters. The position peaked at $1.01M in Q1 2021. 214 funds tracked by Wall St. Rank hold VIR as of Q3 2023.

  • StoneX Group reported no remaining Vir Biotechnology position as of Q3 2023 after selling out during the quarter.
  • StoneX Group sold 11,762 Vir Biotechnology shares in Q3 2023, an estimated $289K.
  • StoneX Group first reported a position in Vir Biotechnology in Q1 2021 and held it in 10 quarters.
  • StoneX Group's Vir Biotechnology position peaked at $1.01M in Q1 2021.
  • 214 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2023.

Based on StoneX Group's 13F filing for Q3 2023, filed 15 Nov 2023.